BioLine RX Stock

BioLine RX Capital Expenditures

Capital Expenditures (CapEx) of BioLine RX (BLRX.TA) as of Mar 14, 2026.

Capital Expenditures

0USD

Last updated: Mar 14, 2026

Capital Expenditures (CapEx) of BioLine RX is 2026 0 USD. Capital Expenditures (CapEx) of BioLine RX was 2025 0 USD. It decreases by % lower compared to the previous year.

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.com.

Frequently Asked Questions about BioLine RX stock

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) BioLine RX since 2006 – with annual values, charts, and detailed analysis.

Cash Flow — BioLine RX

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

All Key Metrics — BioLine RX